uploads/2018/06/Chart-02-6-1.jpg

A Look at Pfizer’s Revenue Trends

By

Updated

Pfizer’s revenue

Pfizer (PFE) reports revenue in two business segments: Innovative Health and Essential Health. As discussed, Pfizer’s top line grew 1% YoY (year-over-year) to $12.9 billion in Q1 2018 from $12.8 million. The chart below shows Pfizer’s revenue since Q1 2017, and its Q2 2018 estimated revenue.

Business segments

In Q1 2018, Innovative Health revenue grew 6% YoY to $7.8 billion, including 3% operating revenue growth and a 3% boost by foreign exchange. Essential Health revenue fell 5% YoY to $5.1 billion, including a 9% operating revenue decline and a 4% boost by foreign exchange.

Revenue by geography

US revenue fell 5% YoY to $6.3 billion in Q1 2018 from ~$6.6 billion, while international revenue grew 8% YoY to $6.6 billion from $6.1 billion. The growth includes 1% operational growth and a 7% boost by foreign exchange.

The SPDR S&P Pharmaceuticals ETF (XPH) invests 4.4% of its holdings in Pfizer, 4.5% in Bristol-Myers Squibb (BMY), 4.5% in Eli Lilly (LLY), and 4.4% in Johnson & Johnson (JNJ).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

More From Market Realist